Role of interleukin-1 in human diseases: pharmacotherapy prospects: A review

Cover Page

Cite item

Full Text

Abstract

According to current concepts, human immunoinflammatory diseases (IIDs), depending on the prevailing mechanisms of immunopathogenesis, are divided into two main categories: autoimmune and autoinflammatory. At the same time, both autoimmune and autoinflammatory mechanisms are involved in the pathogenesis of most IIDs, and the complex interaction of these mechanisms is reflected in the polymorphism of clinical presentation, course variants, outcomes and therapy efficacy. It is suggested that in IIDs, overproduction of cytokines of the interleukin (IL)-1 family, which is one of the key regulators of innate immunity, determines the "crossing" between autoinflammation and autoimmunity mechanisms. Currently, anakinra, a recombinant non-glycosylated analog of the IL-1 receptor antagonist that blocks both IL-1b and IL-1a signaling, and canakinumab, a monoclonal antibody to IL-1b, are used in clinical practice to inhibit the pathological effects of IL-1. Analysis of the treatment outcomes with these drugs suggests that IL-1 inhibition should be considered a promising direction of pharmacotherapy of systemic autoinflammatory diseases and critical conditions associated with hyperinflammation in children and adults.

About the authors

Evgeny L. Nasonov

Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: nasonov@irramn.ru
ORCID iD: 0000-0002-1598-8360

акад. РАН, д-р мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», зав. каф. ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)

Russian Federation, Moscow; Moscow

References

  1. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297
  2. Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. doi: 10.1038/s41584-021-00652-9
  3. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Med. 2014;20(Suppl. 1):S43-58. doi: 10.2119/molmed.2014.00232
  4. Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2016;54(1):60-77 (in Russian)]. doi: 10.14412/1995-4484-2016-60-77
  5. Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev. 2012;12(1):22-30. doi: 10.1016/j.autrev.2012.07.018
  6. Migliorini P, Italiani P, Pratesi F, et al. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev. 2020;19(9):102617. doi: 10.1016/j.autrev.2020.102617
  7. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14-24. doi: 10.1038/nrrheum.2016.166
  8. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. doi: 10.1038/s41584-019-0277-8
  9. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-52. doi: 10.1038/nrd3800
  10. Malcova H, Milota T, Strizova Z, et al. Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now? Front Pharmacol. 2021;11:619273. doi: 10.3389/fphar.2020.619273
  11. Calabrese L, Fiocco Z, Satoh TK, et al. Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases. Br J Dermatol. 2022;186(6):925-41. doi: 10.1111/bjd.20975
  12. Bettiol A, Lopalco G, Emmi G, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019;20(8):1898. doi: 10.3390/ijms20081898
  13. Cavalli G, Dinarello CA. Anakinra Therapy for Non-cancer Inflammatory Diseases. Front Pharmacol. 2018;9:1157. doi: 10.3389/fphar.2018.01157. Erratum in: Front Pharmacol. 2019;10:148.
  14. Stefania S, Colia R, Cinzia R, et al. Off-label use of anti-IL-1 drugs in rheumatic diseases. Int J Immunopathol Pharmacol. 2021;35:20587384211006584. doi: 10.1177/20587384211006584
  15. Maniscalco V, Abu-Rumeileh S, Mastrolia MV, et al. The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720X20959575. doi: 10.1177/1759720X20959575
  16. Cvetkovic RS, Keating G. Anakinra. BioDrugs. 2002;16(4):303-11;discussion 313-4. doi: 10.2165/00063030-200216040-00005
  17. Gram H. Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem Biol. 2016;32:1-9. doi: 10.1016/j.cbpa.2015.12.003
  18. Gram H. The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer. Pharmacol Res. 2020;154:104139. doi: 10.1016/j.phrs.2019.01.023
  19. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
  20. Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3
  21. Насонов Е.Л., Попкова Т.В. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12 [Nasonov EL, Popkova TV. Atherosclerosis: perspectives of anti-inflammatory therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):4-12 (in Russian)]. doi: 10.26442/terarkh20189054-12
  22. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis – from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589-610. doi: 10.1038/s41573-021-00198-1
  23. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0
  24. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-73. doi: 10.1056/NEJMra2026131
  25. Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021;21(11):694-703. doi: 10.1038/s41577-021-00588-x
  26. CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9(3):295-304. doi: 10.1016/S2213-2600(20)30556-7
  27. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752-60. doi: 10.1038/s41591-021-01499-z
  28. Kyriazopoulou E, Huet T, Cavalli G, et al.; International Collaborative Group for Anakinra in COVID-19. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690-7. doi: 10.1016/S2665-9913(21)00216-2
  29. Kyriakoulis KG, Kollias A, Poulakou G, et al. The Effect of Anakinra in Hospitalized Patients with COVID-19: An Updated Systematic Review and Meta-Analysis. J Clin Med. 2021;10(19):4462. doi: 10.3390/jcm10194462
  30. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9
  31. Gilboa M, Bornstein G, Ben-Zvi I, Grossman C. Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. Rheumatol Int. 2020;40(4):663-9. doi: 10.1007/s00296-019-04393-7
  32. Ajeganova S, De Becker A, Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance. Ther Adv Musculoskelet Dis. 2020;12:1759720X20974858. doi: 10.1177/1759720X20974858
  33. Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR Open Rheumatol. 2020;2(5):276-82. doi: 10.1002/acr2.11135
  34. Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021;326(3):230-9. doi: 10.1001/jama.2021.9508
  35. Cremer PC, Sheng CC, Sahoo D, et al. Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. Eur Heart J Open. 2021;1(1):oeab002. doi: 10.1093/ehjopen/oeab002
  36. Generali D, Bosio G, Malberti F, et al. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int J Infect Dis. 2021;104:433-40. doi: 10.1016/j.ijid.2020.12.073
  37. Katia F, Myriam DP, Ucciferri C, et al. Efficacy of canakinumab in mild or severe COVID-19 pneumonia. Immun Inflamm Dis. 2021;9(2):399-405. doi: 10.1002/iid3.400
  38. Mastroianni A, Greco S, Chidichimo L, et al. Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis. Int J Immunopathol Pharmacol. 2021;35:20587384211059675. doi: 10.1177/20587384211059675
  39. Potalivo A, Montomoli J, Facondini F, et al. Sixty-Day Mortality Among 520 Italian Hospitalized COVID-19 Patients According to the Adopted Ventilatory Strategy in the Context of an Integrated Multidisciplinary Clinical Organization: A Population-Based Cohort Study. Clin Epidemiol. 2020;12:1421-31. doi: 10.2147/CLEP.S278709
  40. Ao G, Wang Y, Li A, et al. The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis. J Infect. 2022;84(6):834-72. doi: 10.1016/j.jinf.2022.03.011

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies